Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849444 | 0.87 | PDPK1 (0.39) | ELANECHEK1AURKADAPK3JAK2 | |
| SCHEMBL913992 | 0.75 | CHEK1 (0.42) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL217630 | 0.71 | — | — | |
| SCHEMBL914987 | 0.69 | PDPK1 (0.47) | ELANEHSD17B10KMT2ATSHRRAB9A | |
| SCHEMBL925775 | 0.69 | ELANE (0.30) | ELANE | |
| SCHEMBL913842 | 0.69 | CHEK1 (0.33) | ELANECHEK1AURKADAPK3JAK2 | |
| SCHEMBL914620 | 0.68 | CHEK1 (0.44) | ELANECHEK1AURKADAPK3JAK2 | |
| SCHEMBL11872100 | 0.67 | ELANE (0.58) | ELANECHEK1AURKADAPK3JAK2 | |
| SCHEMBL652836 | 0.65 | PARP1 (0.52) | CHEK1AURKADAPK3JAK2ABL1 | |
| SCHEMBL11207150 | 0.64 | ELANE (0.42) | ELANEDYRK1AKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997027200-A1 | THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-31 | — | — | WO | claimed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| WO-1998054192-A1 | THIENOXAZINONE DERIVATIVES AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054192-A1 | THIENOXAZINONE DERIVATIVES AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998045298-A1 | ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045298-A1 | ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-15 | — | — | WO | disclosed |
| WO-1997048707-A1 | 4H-3,1-BENZOXAZIN-4-ONE DERIVATIVES AND ANALOGS AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997027200-A1 | THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ELANE 353/4885CHEK1 89/4885AURKA 2850/4885 |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CYP51A1, IPO5, TBC1D5 | ELANE 889/4885CHEK1 3264/4885AURKA 392/4885 |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | ELANE 2053/4885CHEK1 3409/4885AURKA 4435/4885 |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | ELANE 2346/4885CHEK1 3040/4885AURKA 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.